# Immunogenicity Risk Profile of Nanobodies

Frontiers in Immunology

12, 632687

DOI: 10.3389/fimmu.2021.632687

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Llamanade: An Open-Source Computational Pipeline for Robust Nanobody Humanization. SSRN Electronic Journal, 0, , . | 0.4 | 1 |
| 2 | Immunogenicity and humanization of singleâ€domain antibodies. FEBS Journal, 2022, 289, 4304-4327. | 2.2 | 60 |
| 3 | Nanobodies for Medical Imaging: About Ready for Prime Time?. Biomolecules, 2021, 11, 637. | 1.8 | 21 |
| 4 | In vitroimmunogenicity prediction: bridging between innate and adaptive immunity. Bioanalysis, 2021, 13, 1071-1081. | 0.6 | 3 |
| 5 | Transportation of Single-Domain Antibodies through the Bloodâ€“Brain Barrier. Biomolecules, 2021, 11, 1131. | 1.8 | 35 |
| 6 | Pharmacokinetics of Single Domain Antibodies and Conjugated Nanoparticles Using a Hybrid near Infrared Method. International Journal of Molecular Sciences, 2021, 22, 8695. | 1.8 | 8 |
| 8 | TRIM28 Selective Nanobody Reduces Glioblastoma Stem Cell Invasion. Molecules, 2021, 26, 5141. | 1.7 | 16 |
| 9 | Targeting Human Papillomavirus-Associated Cancer by Oncoprotein-Specific Recombinant Antibodies. International Journal of Molecular Sciences, 2021, 22, 9143. | 1.8 | 5 |
| 10 | A Small Virus to Deliver Small Antibodies: New Targeted Therapies Based on AAV Delivery of Nanobodies. Microorganisms, 2021, 9, 1956. | 1.6 | 8 |
| 11 | Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129974. | 1.1 | 12 |
| 12 | Nanobodyâ€Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive Immunotherapy. Small, 2021, 17, e2103463. | 5.2 | 20 |
| 13 | Dose escalation biodistribution, positron emission tomography/computed tomography imaging and dosimetry of a highly specific radionuclide-labeled non-blocking nanobody. EJNMMI Research, 2021, 11, 113. | 1.1 | 6 |
| 14 | Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer. EJNMMI Research, 2021, 11, 115. | 1.1 | 5 |
| 15 | Enzymatic ligation of an antibody and arginine 9 peptide for efficient and cell-specific siRNA delivery. Scientific Reports, 2021, 11, 21882. | 1.6 | 3 |
| 16 | A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 183. | 6.9 | 12 |
| 17 | Interference of p53:Twist1 interaction through competing nanobodies. International Journal of Biological Macromolecules, 2022, 194, 24-31. | 3.6 | 4 |
| 18 | Intrabody Targeting HIF-1Î± Mediates Transcriptional Downregulation of Target Genes Related to Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 12335. | 1.8 | 2 |
| 19 | Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration. Antibodies, 2021, 10, 47. | 1.2 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 20 | Isolation of nanobodies with potential to reduce patients' IgE binding to Bet v 1. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1751-1760. | 2.7 | 9 |
| 21 | CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma. OncoImmunology, 2021, 10, 2000699. | 2.1 | 9 |
| 22 | Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. Nanoscale, 2022, 14, 1054-1074. | 2.8 | 22 |
| 23 | Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment. Frontiers in Immunology, 2021, 12, 838082. | 2.2 | 27 |
| 24 | Construction of a Humanized Artificial VHH Library Reproducing Structural Features of Camelid VHHs for Therapeutics. Antibodies, 2022, 11, 10. | 1.2 | 8 |
| 25 | GPC3-targeted immunoPET imaging of hepatocellular carcinomas. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2682-2692. | 3.3 | 23 |
| 26 | Angiogenic biomolecules specific nanobodies application in cancer imaging and therapy; review and updates. International Immunopharmacology, 2022, 105, 108585. | 1.7 | 2 |
| 27 | Biparatopic nanobodies protect mice from lethal challenge with SARSâ€CoVâ€2 variants of concern. EMBO Reports, 2022, 23, e53865. | 2.0 | 18 |
| 28 | Nanobodies: From Serendipitous Discovery of Heavy Chain-Only Antibodies in Camelids to a Wide Range of Useful Applications. Methods in Molecular Biology, 2022, 2446, 3-17. | 0.4 | 1 |
| 29 | Ozoralizumab, a Humanized Anti-TNFÎ± NANOBODYÂ® Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFÎ± IgG. Frontiers in Immunology, 2022, 13, 853008. | 2.2 | 43 |
| 30 | Nanobodies as molecular imaging probes. Free Radical Biology and Medicine, 2022, 182, 260-275. | 1.3 | 19 |
| 31 | AAVâ€mediated delivery of an antiâ€BACE1 VHH alleviates pathology in an Alzheimer's disease model. EMBO Molecular Medicine, 2022, 14, e09824. | 3.3 | 13 |
| 32 | Llamanade: An open-source computational pipeline for robust nanobody humanization. Structure, 2022, 30, 418-429.e3. | 1.6 | 18 |
| 33 | Single-Domain Antibodies for Targeting, Detection, and In Vivo Imaging of Human CD4+ Cells. Frontiers in Immunology, 2021, 12, 799910. | 2.2 | 18 |
| 34 | Diagnosis of Glioblastoma by Immuno-Positron Emission Tomography. Cancers, 2022, 14, 74. | 1.7 | 12 |
| 35 | Improved targeting of human CD4+ T cells by nanobody-modified AAV2 gene therapy vectors. PLoS ONE, 2021, 16, e0261269. | 1.1 | 14 |
| 36 | AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System. Frontiers in Neurology, 2022, 13, 870799. | 1.1 | 4 |
| 37 | Nanobody-based CAR-T cells for cancer immunotherapy. Biomarker Research, 2022, 10, 24. | 2.8 | 51 |

| # | Article | IF | Citations |
|---|---|---|---|
| 38 | Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments. International Journal of Molecular Sciences, 2022, 23, 5009. | 1.8 | 31 |
| 39 | In vivo Visualization of M2 Macrophages in the Myocardium After Myocardial Infarction (MI) Using 68Ga-NOTA-Anti-MMR Nb: Targeting Mannose Receptor (MR, CD206) on M2 Macrophages. Frontiers in Cardiovascular Medicine, 2022, 9, 889963. | 1.1 | 7 |
| 41 | Emerging applications of nanobodies in cancer therapy. International Review of Cell and Molecular Biology, 2022, , 143-199. | 1.6 | 9 |
| 42 | Radiotheranostic Agents in Hematological Malignancies. Frontiers in Immunology, 0, 13, . | 2.2 | 5 |
| 43 | Single-Domain Antibody Theranostics on the Horizon. Journal of Nuclear Medicine, 2022, 63, 1475-1479. | 2.8 | 14 |
| 44 | ImmunoPET in oncology. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2022, 41, 332-339. | 0.1 | 1 |
| 45 | Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment. Biomolecules, 2022, 12, 1146. | 1.8 | 3 |
| 47 | Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells. Vaccines, 2022, 10, 1335. | 2.1 | 3 |
| 48 | Total Chemical Synthesis of a Functionalized GFP Nanobody. ChemBioChem, 2022, 23, . | 1.3 | 5 |
| 49 | Single Domain Antibody application in bacterial infection diagnosis and neutralization. Frontiers in Immunology, 0, 13, . | 2.2 | 9 |
| 50 | Selection of single domain anti-transferrin receptor antibodies for blood-brain barrier transcytosis using a neurotensin based assay and histological assessment of target engagement in a mouse model of Alzheimerâ€™s related amyloid-beta pathology. PLoS ONE, 2022, 17, e0276107. | 1.1 | 7 |
| 51 | CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy. Frontiers in Immunology, 0, 13, . | 2.2 | 4 |
| 52 | Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection. Viruses, 2022, 14, 2485. | 1.5 | 2 |
| 53 | Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting. Theranostics, 2023, 13, 355-373. | 4.6 | 7 |
| 54 | Utilizing Biologics in Drug Desensitization. Current Allergy and Asthma Reports, 2023, 23, 1-11. | 2.4 | 6 |
| 55 | Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment. International Journal of Molecular Sciences, 2022, 23, 15006. | 1.8 | 4 |
| 56 | Screening and identification of an anti-PD-1 nanobody with antitumor activity. Bioscience Reports, 2023, 43, . | 1.1 | 3 |
| 57 | Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy. Frontiers in Immunology, 0, 13, . | 2.2 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 58 | Innovative strategies to study epigenetic regulation and advance precision medicine. , 2024, , 96-111. | | 0 |
| 59 | Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses. Cancer Letters, 2023, 561, 216139. | 3.2 | 5 |
| 60 | Targeting the Brain with Single-Domain Antibodies: Greater Potential Than Stated So Far?. International Journal of Molecular Sciences, 2023, 24, 2632. | 1.8 | 5 |
| 61 | Nanobodies: Robust miniprotein binders in biomedicine. Advanced Drug Delivery Reviews, 2023, 195, 114726. | 6.6 | 7 |
| 62 | T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts. Frontiers in Immunology, 0, 14, . | 2.2 | 8 |
| 63 | A bispecific TÂcell engager recruits both type 1 NKT and VÎ³9VÎ´2-T cells for the treatment of CD1d-expressing hematological malignancies. Cell Reports Medicine, 2023, 4, 100961. | 3.3 | 9 |
| 65 | Nanobodies: A Review of Generation, Diagnostics and Therapeutics. International Journal of Molecular Sciences, 2023, 24, 5994. | 1.8 | 43 |
| 66 | Preparation and characterization of nanobodies targeting SARS-CoV-2 papain-like protease. Protein Expression and Purification, 2023, 207, 106267. | 0.6 | 2 |
| 73 | Construction of Synthetic VHH Libraries in Ribosome Display Format. Methods in Molecular Biology, 2023, , 19-31. | 0.4 | 0 |
| 79 | The potential of monoclonal antibodies for colorectal cancer therapy. , 2023, 40, . | | 0 |